Sunday, Sep 20, 2026

"b-1-617-2-delta-variant"

Phase 3 trial data shows Covaxin to be 77.8% effective against Covid-19

Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.

Latest News

Arvind Kejriwal family gets SIR notices from Delhi Election Commission

4 hours ago
44 killed in Yemen clashes between government forces and Houthis

4 hours ago
Gauhati HC hears PIL challenging EVM technology in Assam Assembly polls

4 hours ago
Aston Villa beat Tottenham 3-2 as Manzambi, Jackson and Buendia score

4 hours ago
LPG consumers must complete Aadhaar authentication for subsidy from October 1

4 hours ago
Barbers boycott duties at temple town Vemulawada

4 hours ago
Telangana emerges as a major opportunity for advanced technologies with 2.6 million-plus MSMEs

5 hours ago
CMC approves Rs 37 crore for Nallagandla-ORR radial road widening

5 hours ago